UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
ZVRA
Zevra Therapeutics, Inc.
ZVRA has the edge over UNH overall, supported by stronger fundamentals and stronger modeled upside.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ZVRA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ZVRA's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ZVRA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.4x | $7.75 | -31% |
| Current | 9.2x | $11.16 | — |
| Fair | 11x | $13.47 | +21% |
| Forward | 14x | $11.16 | — |
| Expensive | 24x | $28.69 | +157% |
Historical ranges are pointers, not guarantees.
ZVRA has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ZVRA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ZVRA, with profitability improving. However, they disagree widely on these estimates.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ZVRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | -32% |
| Q3 2026 | $1.21 | +227% |
| Q2 2026 | $0.94 | +$1.25 |
| Q1 2026 | $2.01 | +$4.01 |
| Q4 2025 | $1.35 | +$3.69 |
| Q3 2025 | $0.37 | +$2.37 |
| Q2 2025 | -$0.31 | +$1.40 |
| Q1 2025 | -$2.00 | -$0.62 |
| Q4 2024 | -$2.34 | -$1.02 |
ZVRA has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ZVRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | +45% |
| Q2 2026 | $39.7M | +53% |
| Q1 2026 | $36.2M | +78% |
| Q4 2025 | $34.1M | +183% |
| Q3 2025 | $26.1M | +605% |
| Q2 2025 | $25.9M | +482% |
| Q1 2025 | $20.4M | +496% |
| Q4 2024 | $12M | -8.9% |
ZVRA has the edge over UNH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +15 points |
| Q2 2026 | 42% | +317 points |
| Q1 2026 | 144% | +170 points |
| Q4 2025 | 27% | +155 points |
| Q3 2025 | 16% | +755 points |
| Q2 2025 | -274% | +260 points |
| Q1 2025 | -26% | +572 points |
| Q4 2024 | -128% | -17 points |
ZVRA has the edge over UNH on profitability, with a higher operating margin.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ZVRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.8M | +136% |
| Q2 2026 | $16.8M | +$20.6M |
| Q1 2026 | $6.1M | +$14.4M |
| Q4 2025 | $5.5M | +$21.8M |
| Q3 2025 | $4.2M | +$22.3M |
| Q2 2025 | -$3.8M | +$15.3M |
| Q1 2025 | -$8.3M | +$7.8M |
| Q4 2024 | -$16.3M | -$20K |
ZVRA has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ZVRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ZVRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +396K shares |
| 1 year | +10% | +5.8M shares |
| 3 years | +78% | +27M shares |
| 5 years | +75% | +26.5M shares |
| Available history | +3231% | +59.9M shares |
ZVRA has 62M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.4M |
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ZVRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q4 2021 | -14.1x | Net Cash |
| Q3 2021 | -17.3x | Net Cash |
| Q2 2021 | -15.3x | Net Cash |
| Q1 2021 | -14.1x | Net Cash |
ZVRA has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ZVRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 45.9 | Neutral |
ZVRA's weekly RSI is 51 (neutral) and its Stochastic is 46 (neutral).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ZVRA PE vs Healthcare Sector
| Metric | ZVRA | Sector median | Relative |
|---|---|---|---|
| PE | 9.2x | 26x | 64% below |
| PE % | 40 | 29 | 11 pts above |
ZVRA has the edge over UNH on valuation relative to its sector.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
ZVRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.7 | 4.8% above |
| 20 week MA | $11.3 | 1.5% below |
| 50 week MA | $10.4 | 7.3% above |
| 100 week MA | $9.66 | 16% above |
| 200 week MA | $7.72 | 45% above |
ZVRA's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.
ZVRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.69 | $11.5 | +72% |
| 2021 | $11.5 | $8.97 | -22% |
| 2022 | $8.97 | $4.29 | -52% |
| 2023 | $4.29 | $6.55 | +53% |
| 2024 | $6.55 | $8.39 | +28% |
| 2025 | $8.39 | $8.87 | +5.7% |
| 2026 YTD | $8.87 | $11.2 | +26% |
ZVRA has the edge over UNH on returns for 2026, with the stronger performance.